Почему для лечения ревматоидного артрита не применяются рекомендуемые дозы метотрексата: кто виноват и что делать?

Автор: Муравьев Ю.В., Насонов Е.Л.

Журнал: Научно-практическая ревматология @journal-rsp

Статья в выпуске: 1 т.55, 2017 года.

Бесплатный доступ

Дискуссия посвящена проблеме применения рекомендуемых для лечения ревматоидного артрита доз метотрексата в рандомизированных клинических сравнительных с генно-инженерными биологическими препаратами исследованиях.

Ревматоидный артрит, метотрексат, рандомизированные клинические исследования, генно-инженерные биологические препараты

Короткий адрес: https://sciup.org/14945784

IDR: 14945784 | DOI: 10.14412/1995-4484-2017-112-114

Список литературы Почему для лечения ревматоидного артрита не применяются рекомендуемые дозы метотрексата: кто виноват и что делать?

Duran J, Bockorny M, Dalal D, et al. Methotrexate dosage as a source of bias in biologic trials in rheumatoid arthritis: a systematic review. Ann Rheum Dis. 2016; 75: 1595-8 DOI: 10.1136/annrheumdis-2016-209383
Kremer JM. Bias? Not so fast. Ann Rheum Dis. 2016; 75(9): 1581-2 DOI: 10.1136/annrheumdis-2016-209505
Visser K, Katchamart W, Loza E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus onrheumatoid arthritis: integrating systematic literature research and expert opinion of a broad internationalpanel of rheumatologists in the 3E Initiative. Ann Rheum Dis. 2009; 68: 1086-93 DOI: 10.1136/ard.2008.094474
Dervieux T, Greenstein N, Kremer J. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum. 2006; 54: 3095-103 DOI: 10.1002/art.22129
Wessels JA, de Vries-Bouwstra JK, Heijmans BT, et al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum. 2006; 54: 1087-95 DOI: 10.1002/art.21726
Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomised, crossover study of oralversus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses >15 mg may be overcome with subcutaneous administration. Ann Rheum Dis. 2014; 73: 1549-51 DOI: 10.1136/annrheumdis-2014-205228
Hazlewood GS, Thorne JC, Pope JE, et al. The comparative effectiveness of oralversus subcutaneous methotrexate for the treatment of early rheumatoid arthritis. Ann Rheum Dis. 2016; 75: 1003-8 DOI: 10.1136/annrheumdis-2014-206504
Braun J, Kä stner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008; 58: 73-81 DOI: 10.1002/art.23144
Islam MS, Haq SA, Islam MN, et al. Comparative efficacy of subcutaneous versus oralmethotrexate in active rheumatoid arthritis. Mymensingh Med J. 2013; 22: 483-8.
Mü ller RB, von Kempis J, Haile SR, et al. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: a retrospective analysis of real-world data from the St. Gallen cohort. Semin Arthritis Rheum. 2015; 45: 28-34 DOI: 10.1016/j.semarthrit.2015.02.009
Gunn J, Panopolou A, Steuer A. Efficacy and tolerability of subcutaneous methotrexate for inflammatory arthritis: a retrospective observational cohort study . Arthritis Rheum. 2014; 66: S1079.
Kremer JM. Let's re-examine these MTX points once again. Ann Rheum Dis. 2016; 75(8): e54 DOI: 10.1136/annrheumdis-2016-209834
Duran J, Felson DT. Why methotrexate suboptimal dosing is a potential source of bias in biologic drugs clinical trials. Ann Rheum Dis. 2016; 75(8): e53 DOI: 10.1136/annrheumdis-2016-209791
Nair SC, Jacobs JW, Bakker MF, et al; Utrecht Arthritis Cohort Study Group. Determining the lowest optimally effective methotrexate dose for individual ra patients using their dose response relation in a tight control treatment approach. PLoS One. 2016 Mar 17; 11(3): e0148791 DOI: 10.1371/journal.pone.0148791
Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014; 73: 492-509 DOI: 10.1136/annrheumdis-2013-204573
Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study -A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006; 54: 26-37 DOI: 10.1002/art.21519
St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004; 50: 3432-43 DOI: 10.1002/art.20568
Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004; 363: 675-81 DOI: 10.1016/S0140-6736(04)15640-7
Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. 2011; 70: 39-46 DOI: 10.1136/ard.2010.137703
Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis. 2009; 68: 1870-7 DOI: 10.1136/ard.2008.101121
Gvozdenovic E, Allaart C, van der Heijde D, et al. When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS). RMD Open. 2016 Apr 28; 2(1): e000221 DOI: 10.1136/rmdopen-2015-000221
Kay J, Westhovens R. Methotrexate: the gold standard without standardisation. Ann Rheum Dis. 2009 Jul; 68(7): 1081-2 DOI: 10.1136/ard.2008.102822

Еще

Статья научная